Literature DB >> 33947685

Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.

Antje Lindemann1, Ameeta A Patel2, Jeffrey N Myers3, Abdullah A Osman3, Lin Tang4, Noriaki Tanaka5, Frederico O Gleber-Netto1, Mason D Bartels1, Li Wang6, Daniel J McGrail7, Shiaw-Yih Lin7, Steven J Frank6, Mitchell J Frederick8.   

Abstract

Despite advances in surgery, chemotherapy, and radiation, there are limited treatment options for advanced head and neck squamous cell carcinoma (HNSCC) and survival remains very poor. Therefore, effective therapies are desperately needed. Recently, selective exploitation of DNA damage and replication stress responses has become a novel approach for cancer treatment. Wee1 kinase and Rad51 recombinase are two proteins involved in regulating replication stress and homologous recombination repair in cancer cells. In this study, we investigated the combined effect of Rad51 inhibitor (B02) and Wee1 inhibitor (AZD1775) in vitro and in vivo in various HNSCC cell lines. Clonogenic survival assays demonstrated that B02 synergized with AZD1775 in vitro in all HNSCC cell lines tested. The synergy between these drugs was associated with forced CDK1 activation and reduced Chk1 phosphorylation leading to induction of excessive DNA damage and replication stress, culminating in aberrant mitosis and apoptosis. Our results showed that elevated Rad51 mRNA expression correlated with worse survival in HNSCC patients with HPV-positive tumors. The combination of B02 and AZD1775 significantly inhibited tumor growth in vivo in mice bearing HPV-positive HNSCC tumors as compared to HPV-negative HNSCC. This differential sensitivity appears to be linked to HPV-positive tumors having more in vivo endogenous replication stress owing to transformation by E6 and E7 oncogenes. Furthermore, addition of B02 radiosensitized the HPV-negative HNSCC tumors in vitro and in vivo In conclusion, our data implicate that a novel rational combination with Rad51 and Wee1 inhibitors holds promise as synthetic lethal therapy, particularly in high-risk HPV-positive HNSCC. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33947685      PMCID: PMC8295235          DOI: 10.1158/1535-7163.MCT-20-0252

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  49 in total

1.  Inhibition of homologous recombination in human cells by targeting RAD51 recombinase.

Authors:  Fei Huang; Olga M Mazina; Isaac J Zentner; Simon Cocklin; Alexander V Mazin
Journal:  J Med Chem       Date:  2012-03-19       Impact factor: 7.446

Review 2.  Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place.

Authors:  Panagiotis Kotsantis; Eva Petermann; Simon J Boulton
Journal:  Cancer Discov       Date:  2018-04-13       Impact factor: 39.397

3.  Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.

Authors:  Hiroshi Hirai; Yoshikazu Iwasawa; Megumu Okada; Tsuyoshi Arai; Toshihide Nishibata; Makiko Kobayashi; Toshifumi Kimura; Naoki Kaneko; Junko Ohtani; Kazunori Yamanaka; Hiraku Itadani; Ikuko Takahashi-Suzuki; Kazuhiro Fukasawa; Hiroko Oki; Tadahiro Nambu; Jian Jiang; Takumi Sakai; Hiroharu Arakawa; Toshihiro Sakamoto; Takeshi Sagara; Takashi Yoshizumi; Shinji Mizuarai; Hidehito Kotani
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

4.  HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells.

Authors:  Rossella Marullo; Erica Werner; Hongzheng Zhang; Georgia Z Chen; Dong M Shin; Paul W Doetsch
Journal:  Carcinogenesis       Date:  2015-09-08       Impact factor: 4.944

5.  Elevated levels of Rad51 recombination protein in tumor cells.

Authors:  Elke Raderschall; Karen Stout; Susanne Freier; Vanessa Suckow; Susann Schweiger; Thomas Haaf
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

6.  Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

Authors:  Khanh Do; Deborah Wilsker; Jiuping Ji; Jennifer Zlott; Tomoko Freshwater; Robert J Kinders; Jerry Collins; Alice P Chen; James H Doroshow; Shivaani Kummar
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

7.  UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

Authors:  Q Wang; S Fan; A Eastman; P J Worland; E A Sausville; P M O'Connor
Journal:  J Natl Cancer Inst       Date:  1996-07-17       Impact factor: 13.506

8.  Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay.

Authors:  S N Powell; J S DeFrank; P Connell; M Eogan; F Preffer; D Dombkowski; W Tang; S Friend
Journal:  Cancer Res       Date:  1995-04-15       Impact factor: 12.701

9.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.

Authors:  David J Adelstein; Yi Li; George L Adams; Henry Wagner; Julie A Kish; John F Ensley; David E Schuller; Arlene A Forastiere
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

10.  Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer.

Authors:  N Wang; T Zhan; T Ke; X Huang; D Ke; Q Wang; H Li
Journal:  Br J Cancer       Date:  2014-01-14       Impact factor: 7.640

View more
  3 in total

1.  Inhibiting WEE1 and IKK-RELA Crosstalk Overcomes TNFα Resistance in Head and Neck Cancers.

Authors:  Carter Van Waes; Ethan L Morgan; Zhengbo Hu; Ramya Viswanathan; Hui Cheng; Jianghong Chen; Xinping Yang; Angel Huynh; Paul Clavijo; Yi An; Yvette Robbins; Christopher Silvin; Clint Allen; Pinar Ormanoglu; Scott Martin; Shaleeka Cornelius; Anthony Saleh; Zhong Chen
Journal:  Mol Cancer Res       Date:  2022-06-03       Impact factor: 6.333

2.  Hydroxygenkwanin Increases the Sensitivity of Liver Cancer Cells to Chemotherapy by Inhibiting DNA Damage Response in Mouse Xenograft Models.

Authors:  Chin-Chuan Chen; Chi-Yuan Chen; Shu-Fang Cheng; Tzong-Ming Shieh; Yann-Lii Leu; Wen-Yu Chuang; Kuang-Ting Liu; Shir-Hwa Ueng; Yin-Hwa Shih; Li-Fang Chou; Tong-Hong Wang
Journal:  Int J Mol Sci       Date:  2021-09-09       Impact factor: 6.208

3.  Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic.

Authors:  Yuewen Zhang; Lei Wu; Zhao Wang; Jinpeng Wang; Shrabasti Roychoudhury; Bartlomiej Tomasik; Gang Wu; Geng Wang; Xinrui Rao; Rui Zhou
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.